Data on the utility of MeMed BV to be presented at ACEP25

Sept. 4, 2025—MeMed announced that several oral presentations at the American College of Emergency Physicians Scientific Assembly 2025, Sept. 7–10 in Salt Lake City, will showcase clinical evidence supporting the utility of MeMed BV, an FDA-cleared test that distinguishes between bacterial and viral infections based on the body’s immune response. The presentations span multiple leading U.S. medical centers and include real-world data, randomized controlled trial results, and insights into the test’s role in supporting clinical decisions with challenging patient populations, such as people who are immunocompromised and the elderly. “Collectively, these studies underscore MeMed BV’s potential to support decision-making in emergency departments and aid clinicians in their efforts to reduce unnecessary antibiotic use and unnecessary admissions while lowering health care costs,” according to a press release from the company.